SARS-CoV-2 Omicron subvariants such as BA.2.12.1, BA.4 and BA.5 have been spreading rapidly and become dominant worldwide. Here we report the homologous or heterologous booster effects of S-268019-b, a recombinant spike protein vaccine with the squalene-based adjuvant A-910823 in cynomolgus macaques. In macaques which had been primed with S-268019-b or mRNA vaccines, boosting with S-268019-b enhanced neutralizing antibodies (NAb) against ancestral SARS-CoV-2. Since boosting with the antigen without adjuvant did not efficiently restore NAb titers, adjuvant A-910823 was essential for the booster effect. Importantly, boosting with S-268019-b enhanced NAb against all of the Omicron subvariants we tested, including BA.2.12.1, BA.4 and BA.5, in comparison to two vaccine doses. Additionally, expansion of Omicron-specific B cells was confirmed after boosting with S-268019-b. These results indicate that a booster dose of S-268019-b with the adjuvant enhances the neutralization breadth.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640394 | PMC |
| http://dx.doi.org/10.1016/j.vaccine.2022.10.092 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The emerging of emergent SARS-CoV-2 subvariants has reduced the protective efficacy of COVID-19 vaccines. Therefore, novel COVID-19 vaccines targeting these emergent variants are needed. We designed and prepared CoV072, an mRNA-based vaccine against SARS-CoV-2 Omicron (EG.
View Article and Find Full Text PDFGenomic and epidemiological analysis of SARS-CoV-2 variants isolated in Guinea: a routine sequencing implementation.
BMC Infect Dis
January 2025
Centre de Recherche et de Formation en Infectiologie de Guinée (CERFIG), Université Gamal Abder Nasser de Conakry, Conakry, Guinea.
Background: Several variants of SARS-CoV-2 have a demonstrated impact on public health, including high and increased transmissibility, severity of infection, and immune escape. Therefore, this study aimed to determine the SARS-CoV-2 lineages and better characterize the dynamics of the pandemic during the different waves in Guinea.
Methods: Whole genome sequencing of 363 samples with PCR cycle threshold (Ct) values under thirty was undertaken between May 2020 and May 2023.
[Clinical Impact of Current Variants in COVID-19 Patients: Clinical Characteristics in Variant EG.5].
Mikrobiyol Bul
October 2024
University of Health Sciences, Ankara Bilkent City Health Application and Research Center, Clinic of Medical Microbiology, Ankara, Türkiye.
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has mutated at a high rate since the beginning of the pandemic, leading to the formation of different variants. Alpha, Beta, Gamma, Delta and Omicron have emerged as concerning variants identified by the World Health Organization (WHO). The Omicron variant and its sublineages became dominant worldwide in 2022.
View Article and Find Full Text PDFGenetic Conservation and Diversity of SARS-CoV-2 Envelope Gene Across Variants of Concern.
J Med Virol
January 2025
Department of Microbiology, Howard University College of Medicine, Washington, District of Columbia, USA.
Article Synopsis
- The study analyzes the envelope (E) protein of SARS-CoV-2, highlighting its importance in viral assembly, release, and overall virulence, while assessing the conservation and mutation patterns across different variants of concern (VOCs).
- Mutations were identified in various strains, notably B.1.351 and Omicron, that could compromise the effectiveness of current diagnostic RT-PCR assays by altering the E protein's stability.
- The research underscores the need for ongoing surveillance of viral mutations to enhance diagnostic strategies and understand the evolving nature of SARS-CoV-2.
Characteristics of patients with non-severe infections of different SARS-CoV-2 omicron subvariants in China.
Front Med (Lausanne)
December 2024
Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China.
Objective: The aim of this study was to explore the clinical characteristics of patients infected with different Omicron subvariants presenting non-severe disease, evaluate the safety and efficacy of Azvudine for treatment of COVID-19, in order to broaden understanding of Omicron subvariant infections.
Method: A total of 244 individuals with Omicron subvariant (BA.2.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!